1. CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data

3. Program Overview

4. Should Clinicians Consider a CDK 4 and 6 Inhibitor in Combination With ET as Upfront Strategy?

5. Assessing the New Data

6. PALOMA-1: Phase 2 Study Design

7. PALOMA-1: Overall Survival

8. Is PFS Important Enough for Considering Palbociclib in Clinical Practice?

9. MONALESSA-2: Study Design

10. MONALEESA-2: PFS Update

11. MONALEESA-2 Health-Related Quality of Life

12. MONARCH-2: Study Design

13. MONARCH-2: PFS (ITT)

14. PALOMA-3 and MONARCH-2 Characteristics

15. MONARCH-2: ORR

16. MONARCH-2: Incidence of Grade 2/3 Diarrhea

17. Cumulative Incidence of All-Casualty AEs >15% During the First 5 Years of Palbociclib Treatment (N=83)

18. Managing Neutropenia Associated With CDK 4 and 6 Inhibitors

19. When Patients Progress After Treatment With CDK 4 and 6 Inhibitors: Unanswered Questions

20. Assessing Biomarker Data

21. Take Home Messages

22. Take Home Messages (cont)

23. CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data

24. Abbreviations (cont)

25. Abbreviations (cont)